Please assess the completion status of the following clinical trial:

Trial Title: Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80 years.~* Patients with hepatocellular carcinoma (BCLC, stageB/C) proved by histopathology or proved by CT or MRI imaging system, relapsed after previous therapy and no effective therapies known at this time.~* Life expectancy of ≥ 12 weeks.~* WBC\>3.0×10\^9/L, LYMPH\> 0.8×10\^9/L, Hb\>85g/L, PLT\>50×10\^9/L, Cre\<1.5×the upper limit of normal value.~* iNKT\>10 cell/mL in peripheral blood mononuclear cell (PBMC).~* Able to understand and sign the informed consent.~Exclusion Criteria:~* Any uncontrolled systematic disease: hypertension, heart disease, and et al.;~* Portal vein tumor thrombus, central nervous system tumor metastasis, or combined with other tumors;~* Receiving radiochemotherapy, local therapy, or targeting drugs within 4 weeks prior to this treatment;~* Unstable immune systematic diseases or infectious diseases;~* Combined with AIDS or syphilis;~* Patients with history of stem cell or organ transplantation;~* Patients with allergic history to related drugs and immunotherapy;~* Patients with complications associated with liver diseases: moderate or severe pleural effusion, pericardial effusion, ascites, or gastrointestinal hemorrhage;~* Pregnant or lactating subjects;~* Unsuitable subjects considered by clinicians.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TAE/TACE+iNKT for unresectable HCC (Type: EXPERIMENTAL): TAE/TACE combined with autologous iNKT cells infusion will be applied for patients in experimental group. TAE/TACE will be performed at 0th and 4th week. 5×10\^8-10\^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 9th, 11th week after first TAE/TACE therapy.
- TAE/TACE for unresectable HCC (Type: OTHER): TAE/TACE will be conducted at 0th week and 4th week.

Based on this trial design, predict the completion outcome and termination type (if applicable).